Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Atossa Genetics Inc
ATOS | US
5.15
USD-0.21
-4.01%
ATOS | US
Loading StockChartView...
About Atossa Genetics Inc
Sector
Healthcare
Industry
Diagnostics & Research
Earnings date
30/06/2024
As of date
06/04/2026
Close
5.15
Open
5.41
High
5.41
Low
5.10
Atossa Therapeutics Inc. a clinical-stage biopharmaceutical company focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen an active metabolite of tamoxifen which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics Inc. in January 2020. Atossa Therapeutics Inc. was founded in 2008 and is headquartered in Seattle Washington.
View LessATOS | US
Risk
89.6
Sharpe
-0.70
Luna's Score
40/100
Recommendation
Sell
Luna says (ATOS | US)
What's Working
Value Stock (Price to Book < 3)
What's not Working
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
104.5%1 month
89.6%3 months
106.0%6 months
87.9%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.27
Debt to equity
-
Debt to assets
-
Ent. to EBITDA
2.01
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-30.55M
MarketCap
647.65M
MarketCap(USD)
647.65M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-28.00
Short ratio
22.41
Short perc.
10.28
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
1.50
Range1M
1.73
Range3M
7.03
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.68
Price X volume
281.74K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 2.01 | 12.67 | Cheaper |
| Ent. to Revenue | - | 44.00 | - |
| PE Ratio | - | 40.09 | - |
| Price to Book | 2.27 | 77.50 | Cheaper |
| Dividend Yield | - | 1.18 | - |
| Std. Deviation (3M) | 106.01 | 59.59 | Riskier |
| Debt to Equity | - | -14.36 | - |
| Debt to Assets | - | 0.34 | - |
| Market Cap | 647.65M | 13.71B | Emerging |
